Recombinant activated Factor VII as a hemostatic agent in very low birth weight preterms with gastrointestinal hemorrhage and disseminated intravascular coagulation

Doris Fischer, Rolf Schloesser, Horst Buxmann, Alex Veldman

Research output: Contribution to journalArticleResearchpeer-review

9 Citations (Scopus)


OBJECTIVE: Acute hemorrhage in preterm infants leads immediately to a life-threatening event because of the small circulating blood volume. The beneficial use of recombinant activated Factor VII (rFVIIa; NovoSeven, NovoNordisk, Gentofte, Denmark) as hemostatic treatment in neonates with hemorrhagic shock has been described. Necrotizing enterocolitis is a challenge in neonatology as the disease represents one of the leading causes of mortality in preterm infants. We report on the use of rFVIIa in very low birth weight (
Original languageEnglish
Pages (from-to)337 - 342
Number of pages6
JournalJournal of Pediatric Hematology/Oncology
Issue number5
Publication statusPublished - 2008
Externally publishedYes

Cite this